XTalks

JULY 10, 2024

Unlike traditional testing methods that require samples to be sent to central laboratories, this test utilizes a blood sample from the fingertip to detect HCV RNA, delivering results in approximately one hour. “This is the first HCV RNA detection technology sensitive enough for active case finding at the point of care.

RNA 97

RNA In-Vitro Genotype Marketing 97

XTalks

JULY 14, 2022

Over time, even the use of Krystexxa can lead to the development of antibodies against it, reducing its effectiveness. Early data also showed that methotrexate could prevent the formation of anti-drug antibodies. This is why methotrexate was paired with it, as methotrexate is used to treat inflammatory conditions like arthritis.

FDA Approval 105

FDA Approval Antibody Trials Drugs 105

XTalks

FEBRUARY 3, 2022

The anti-amyloid antibody will go head-to-head against Biogen’s Aduhelm (aducanumab), which continues to face controversy over its approval given questions about its lacklustre clinical benefit. Related: Eli Lilly Pursues RNA Editing in New Partnership with ProQR. Last year, Lilly announced a new, $1.5

Manufacturing 52

Manufacturing RNA Life Science Antibody 52

pharmaphorum

SEPTEMBER 22, 2022

When exposed to a virus, one’s immune system develops antibodies in response to foreign antigens, with or without a vaccine. “Sometimes the difference between life and death is your immune system being ready within two days versus within five days. Antibodies cover the pathogen of the virus and neutralise it.

Vaccine 97

Vaccine Vaccination Antibody Clinical Trials 97

Delveinsight

JULY 29, 2021

billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets. An antisense treatment, BIIB080 potentially aims at microtubule-linked protein tau (MAPT) messenger RNA (mRNA) and impedes tau protein production.

Drugs 98

Drugs Protein Life Science Development 98

The Pharma Data

DECEMBER 8, 2020

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . European venture capital firm Forbion rounded up $545 million for its fifth life sciences fund. Laying down a new track for RNA processing, Remix launched with $81 million in financing. Reduce cost.

RNA 52

RNA Antibody Life Science Protein 52

pharmaphorum

AUGUST 22, 2022

It’s a naturally occurring process, but you can reprogramme that messenger RNA to do what you want and then put it into the body and use it for a multitude of indications,” Torrance states. The Fund has owned Genmab , a Danish biotechnology company that creates antibody therapies for cancer, for 12 years. About the author

Gene Therapy 102

Gene Therapy Antibody Gene Medicine 102

pharmaphorum

AUGUST 11, 2020

MDC already has established working relationships with many life science organisations across the region and provides input into the LEP’s regional life sciences strategy. The funding will be used to create a regional consortium and develop the full stage bid.

Medicine 52

Medicine Life Science Development RNA 52

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. In a study where the antiviral activity of Sunlenca was evaluated in combination with an optimized background regimen, 87.5 percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Gene 111

XTalks

MARCH 10, 2021

While molecular PCR-based tests remain the gold standard for the detection of SARS-CoV-2 viral RNA, rapid antigen tests are useful for screening purposes. Adding to the testing repertoire is the first T cell-based test that can detect previous infection, akin to antibody tests. 1. First T-Cell Test from Adaptive Biotechnologies.

Protein 98

Protein RNA Antibody Production 98

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Gibbs received his BSc in Applied Biology from the University of Wales Institute of Science and Technology, and earned his Ph.D. This is just the beginning; the potential is enormous,” he says. About Whitelab Genomics.

Genome 105

Genome Genomics Medicine Development 105

XTalks

JUNE 4, 2024

Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies. In the past, the majority of drugs evaluated in the clinical pharmacology space were small molecules.

Clinical Development 110

Clinical Development Development Clinical Trials Clinical Trials 110

XTalks

JUNE 5, 2023

RSV belongs to the family of negative-strand RNA viruses and was first identified in 1955. AstraZeneca revealed promising Phase III results for its single dose long-acting antibody, nirsevimab , against RSV. The global RSV vaccine and antibody market is expected to reach $2.56 The vaccine demonstrated 83.7 billion by 2028.

Vaccine 98

Vaccine Vaccination FDA Approval Protein 98

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Also, exosomes are mostly being used for the detection of circulating RNA and microRNA. “An Regulatory Approvals for Exosome-Based Liquid Biopsies.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

JANUARY 25, 2021

Although TaiMed Biologics’ antibody drug Trogarzo is an intravenous formulation that is administered once every 14 days, it must be used in conjunction with other antiretroviral drugs. Patients in the studies were virologically suppressed (HIV-1 RNA less than 50 copies/milliliter) prior to initiation of treatment with Cabenuva.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

This process is different from commonly used antibody-based processes and enables the company to overcome a key hurdle in exosome preparation, i.e. remaining antibodies in the final preparation. ABOUT SARTORIUS The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.

Manufacturing 52

Manufacturing Containment Life Science Production 52

XTalks

AUGUST 30, 2022

Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Vornov, nusinersen is driving much of what is being currently seen in drug development.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

DECEMBER 18, 2023

This novel modality emerged when pharmaceutical developers used non-antibody-based entities as targeting ligand to develop targeted therapeutics. Similar to the structure of the antibody drug conjugates, these next generation drug conjugates use a non-antibody-based targeting ligand, a cytotoxic payload and a linker.

Drugs 40

Drugs FDA Approval Antibody Development 40

The Pharma Data

JANUARY 6, 2021

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Based on its proprietary technology, the company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.

Vaccine 52

Vaccine Vaccination Development Production 52

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Life Science 111

Life Science Vaccine Vaccination Gene 111

XTalks

MAY 29, 2024

In its acquisitions, J&J also acquired antibody-drug conjugate (ADC) developer Ambryx and cardiac med tech Laminar along with more than 50 smaller, early-stage licensing deals and partnerships. billion to acquire Telavant for an anti-TL1A antibody, an inflammatory bowel disease candidate ready for Phase III trials.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccine 52

XTalks

MARCH 25, 2025

Our 5CapQ assay is an immunoassay-based approach that utilizes an immobilized 5 cap-specific antibody to capture mRNA that has a 5 cap, Dr. Lacey explains. Another risk involves impurities, including double-stranded RNA, which can cause unwanted immunogenicity. InDevRs approach has been developed to streamline this process.

Vaccine 59

Vaccine Vaccination Immune Response RNA 59

XTalks

FEBRUARY 11, 2025

In 2010, the FDA approved PCV13 for children, extending protection to six additional serotypes by stimulating the bodys production of antibodies, similar to the response seen with PCV7. of patients on Genvoya and 80% of those on Stribild achieved HIV-1 RNA levels below 50 copies/mL. At Week 144, 84.2% Additionally, 81.1%

Sales 66

Sales FDA Approval Vaccine Vaccination 66

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92